At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 21 enrolled
Drug / intervention
Acalabrutinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Phase 1b Study of ACP 196 in Subjects With Relapsed or Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
In Brief
A Phase 1 clinical trial evaluating Acalabrutinib for Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL). Completed, enrolled 21 participants across 7 sites in 2 countries.
Detailed Summary
To characterize the safety profile of acalabrutinib in subjects with relapsed or refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom, United States
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartAug 2014
Primary CompletionJun 2020
Study CompletionOct 2024
TodayJul 2026
First PostedApr 14, 2014
Enrollment StartAug 7, 2014
Primary CompletionJun 30, 2020
Study CompletionOct 4, 2024
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 12.2 years ago
Interventions
Acalabrutinibdrug